Emmaus Life Sciences to Participate in the Cantor Global Healthcare Conference
TORRANCE, Calif.--(BUSINESS WIRE)--Oct 2, 2018--Emmaus Life Sciences, Inc. (Emmaus), a leader in sickle cell disease treatment, announced today that Kurt Kruger, Chief Financial Officer, will present at the 2018 Cantor Global Healthcare Conference on Wednesday, October 3, 2018, at 9:45 a.m. ET in New York, New York.
About Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan disease. Its lead product, Endari, demonstrated positive clinical results in the completed Phase 3 clinical trial for sickle cell anemia and sickle ß0-thalassemia and has received U.S. FDA approval. Visit: http://www.emmausmedical.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181002005693/en/
CONTACT: LaVoie Health Science
Katie Gallagher, 617-374-8800 x109
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL RESEARCH SCIENCE GENERAL HEALTH
SOURCE: Emmaus Life Sciences, Inc.
Copyright Business Wire 2018.
PUB: 10/02/2018 10:26 AM/DISC: 10/02/2018 10:26 AM